证券代码：600285 证券简称：羚锐制药 公告编号：2026-006 号 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南羚锐制药股份有限公司 关于大股东部分股份质押的公告 重要内容提示: 河南羚锐集团有限公司（以下简称"羚锐集团"）持有河南羚锐制药股 份有限公司（以下简称"公司"）股票 121,817,898 股，占公司总股本的 21.48%。 本次质押 550,000 股后，羚锐集团累计质押本公司股份 37,900,000 股，占其持 股数量比例为 31.11%，占公司总股本的 6.68%。 截至本公告披露日，羚锐集团及其一致行动人持有本公司股份累计质押 数量为 37,900,000 股，占公司总股本的 6.68%。 近日，公司接到羚锐集团股份质押的通知，羚锐集团将其持有的公司无限售 流通股 550,000 股质押给河南农村商业银行股份有限公司新县支行，具体如下： 一、本次股份质押基本情况 1.本次股份质押基本情况 | 股东名称 | 是否为 | 本次质押 | 是否为 | 是否补 | 质押 | | 质押 | | 占其所 ...

证券代码：600285 证券简称：羚锐制药 公告编号：2026-005 号 河南羚锐制药股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，河南羚锐制药股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的铝碳酸镁咀嚼片《药品注册证书》，现将相关情况公告如下： 一、 药品的基本情况 药品名称：铝碳酸镁咀嚼片 剂型：片剂 规格：0.5g 注册分类：化学药品 4 类 处方药/非处方药：非处方药 上市许可持有人：河南羚锐制药股份有限公司 生产企业：河南羚锐制药股份有限公司 药品批准文号：国药准字 H20263652 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。同意本品按（甲类） 非处方药管理。 二、药品的其他情况 截至目前，铝碳酸镁咀嚼片公司累计研发投入约 249.6 万元。 三、对公司的影响 本次公司取得铝碳酸镁咀嚼片《药品注册证书》，进一步丰富了公司产品线， 有利于提高公司的市场竞争力。根据国家相关 ...

Investment Rating - The report suggests a positive investment outlook for the innovative drug sector, highlighting potential opportunities due to upcoming clinical data and successful overseas clinical progress of pipelines [2][4]. Core Insights - The chemical products sector is experiencing significant price increases due to rising international oil prices and high overseas energy costs, particularly affecting solvent products which are difficult to stockpile [1][10]. - The raw material pharmaceutical products are expected to see price increases as upstream raw material costs rise, with downstream clients maintaining low inventory levels since April 2023, indicating a potential for sustained price increases and profit elasticity [1][10]. - The report emphasizes the importance of the PI3K/AKT/mTOR signaling pathway in cancer treatment, with renewed focus on PI3K inhibitors, particularly following Novartis's acquisition of Synnovation Therapeutics' PI3Kα inhibitor SNV4818 [34][35][36]. Summary by Sections Raw Materials - The report notes that the pharmaceutical raw material sector is poised for price increases due to rising upstream costs and low inventory levels among clients, which could lead to sustained profitability [1][10]. Pharmaceuticals - Novartis announced a $2 billion upfront payment and up to $1 billion in milestone payments to acquire Synnovation Therapeutics' PI3Kα inhibitor SNV4818, indicating a strategic focus on differentiated therapies in the HR+/HER2- breast cancer market [2][34]. Medical Devices - Innovative products in the medical device sector are expanding into international markets, with companies like MicroPort receiving CE certification for pediatric applications of their surgical robots, enhancing their global brand presence [3][11]. Biologics - The report highlights the promising results of the oral GLP-1 Aleniglipron, which showed significant weight loss in clinical trials, suggesting a shift towards oral formulations that improve patient compliance and reduce logistics costs [3][12]. Traditional Chinese Medicine - The report suggests monitoring undervalued high-dividend assets within the traditional Chinese medicine sector as companies begin to release their performance results [3][12]. Healthcare Services and Consumer Healthcare - The report discusses the upcoming release of the DRG/DIP 3.0 version by the National Healthcare Security Administration, expected to be published around July 2023, which will provide insights into the evolving healthcare payment landscape [3][12]. Investment Recommendations - The report recommends focusing on core sectors such as small nucleic acids, bispecific antibodies, and ADCs, while also identifying opportunities during earnings forecast windows and major clinical data release events [2][4].

证券代码：600285 证券简称：羚锐制药 公告编号：2026-004 号 河南羚锐制药股份有限公司 关于大股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1 1.本次股份质押基本情况 | | 是否 | | 是否为 限售股 | | | 质押 | | 占其 | 占公 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 为控 | 本次质押 | | 是否补 | 质押起 | | | 所持 | 司总 | 质押融资 | | 股东名称 | | | （如是， | | | 到期 | 质权人 | | | | | | 股股 | 股数 | | 充质押 | 始日 | | | 股份 | 股本 | 资金用途 | | | | | 注明限 | | | 日 | | | | | | | 东 | | | | | | | 比例 | 比例 | | | | | | 售类型） | | | | | | | | 河南羚锐集团有限公司（以下简称"羚锐集团"） ...

Core Viewpoint - The article highlights the investment potential of Lingrui Pharmaceutical (600285.SH), a company that operates in a traditional business model yet demonstrates strong financial performance and growth potential, often overlooked in the A-share market [4][6]. Financial Performance - In 2024, Lingrui Pharmaceutical achieved a total revenue of 3.5 billion yuan, representing a year-on-year growth of 5.7%, and a net profit of 720 million yuan, up 27.2% year-on-year [7]. - For the first three quarters of 2025, the company reported a total revenue of 3.04 billion yuan, a 10.2% increase year-on-year, and a net profit of 650 million yuan, reflecting a 13.4% growth [8][10]. Business Model and Product Demand - The company's business model focuses on selling pain relief plasters, which are essential for consumers, indicating a strong brand moat and consistent demand even in adverse economic conditions [12]. - Lingrui's products, particularly in the orthopedic pain relief sector, have a high acceptance rate among consumers, with significant market share and annual sales exceeding 1 billion plasters for its "Two Tigers" series [16]. Profitability and Cost Management - The gross margin for the plaster products reached 79.0% in 2024, indicating that nearly 80 yuan of every 100 yuan in sales is profit [17]. - The company has optimized its sales expenses over recent years, transitioning from a high-cost model to a more efficient one, which has positively impacted net profits [21][22]. Strategic Expansion - The acquisition of Yinggu Pharmaceutical in 2025 marks Lingrui's first foray into external growth, adding a new product line for allergic rhinitis treatment, although the immediate financial contribution from this acquisition is limited [13][14]. - This acquisition is seen as a strategic move to address market ceiling concerns in the plaster industry and diversify the company's product offerings [15]. Cash Flow and Shareholder Returns - Lingrui reported a net cash flow from operating activities of 880 million yuan in 2024, significantly exceeding its net profit, indicating strong cash generation capabilities [24]. - The company has a robust dividend policy, distributing 450 million yuan in cash dividends in 2023 and 510 million yuan in 2024, with payout ratios of 79.4% and 70.6% respectively, providing attractive returns to investors [27]. Market Position and Future Outlook - Lingrui is characterized as a stable player in the A-share market, with strong brand recognition and high gross margins, positioning it well for future growth [29]. - The integration of Yinggu Pharmaceutical is expected to open new markets for the company, potentially leading to a second growth curve [30].

Group 1 - The Chinese medicine sector saw a rise of 0.54% on January 20, with *ST Changyao leading the gains [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] - Notable gainers in the Chinese medicine sector included *ST Changyao with a closing price of 0.53, up 20.45%, and ST Xiangxue with a closing price of 9.72, up 7.05% [1] Group 2 - The Chinese medicine sector experienced a net outflow of 23.25 million yuan from major funds, while retail investors saw a net inflow of 20.95 million yuan [2] - The top stocks by net inflow from retail investors included *ST Changyao and ST Xiangxue, with retail inflows of 2.20 million yuan and 4.16 million yuan respectively [3] - Major funds showed a significant net outflow in stocks like Zhongsheng Pharmaceutical and Yiling Pharmaceutical, with net outflows of 10.68 million yuan and 5.57 million yuan respectively [3]

Core Viewpoint - Henan Lingrui Pharmaceutical Co., Ltd. has established itself as a household name in the pain relief patch market through innovative production techniques and product development. Group 1: Production Innovations - The company utilizes smart manufacturing technologies, including self-developed digital extraction equipment, to enhance the efficiency, environmental sustainability, and energy conservation of traditional Chinese medicine extraction [2][3]. - A centralized control center monitors over 300 production data points in real-time, ensuring quality stability across different batches of herbal extracts [3]. - The integration of an intelligent logistics and warehousing system has created a "digital highway" from production to shipping, incorporating advanced technologies such as AGV systems and drug traceability [3]. Group 2: Product Development - Lingrui Pharmaceutical has expanded its product line beyond traditional patches, introducing innovative products like the indomethacin patch, which employs advanced laser micropore technology for enhanced functionality [4]. - The company is actively developing new products, including a novel nasal spray for treating cold symptoms, which is expected to broaden its therapeutic applications and clinical value [5]. - The annual sales of the "Two Tigers" patch series have exceeded 1 billion patches, covering various medical fields such as orthopedics, neurology, respiratory medicine, anesthesiology, dermatology, and pediatrics [5]. Group 3: Investment in R&D - Lingrui Pharmaceutical commits 3% to 5% of its annual revenue to research and development, establishing high-level platforms such as a national enterprise technology center and a postdoctoral research workstation [5]. - The company's approach demonstrates that the heritage of traditional brands can serve as a foundation for innovation, enabling them to navigate market cycles and achieve high-quality growth [5].

Core Insights - The company, Lingrui Pharmaceutical, has established itself as a household name in the production of medicated plasters, leveraging advanced technology and innovation to enhance product quality and production efficiency [1][2][3] Group 1: Production and Technology - Lingrui Pharmaceutical has implemented smart manufacturing systems, including a digital extraction process that ensures the quality stability of traditional Chinese medicine extracts [1] - The company has developed an integrated ERP data platform that connects sales, production, and inventory data, allowing for real-time intelligent production scheduling and energy-efficient operations [2] - The production facility is capable of producing 10,000 medicated plasters per minute, showcasing the efficiency of its smart manufacturing processes [1] Group 2: Product Development and Market Position - The company has expanded its product line through continuous research and development, with its "Two Tigers" medicated plaster series achieving annual sales exceeding 1 billion plasters [3] - Lingrui Pharmaceutical is set to launch a new innovative drug, a nasal spray for treating cold symptoms, which will broaden its therapeutic offerings and enhance clinical value [3] - The company invests 3% to 5% of its annual revenue into research and development, establishing high-level platforms such as a national enterprise technology center and a postdoctoral research workstation [3]

证券代码：600285 证券简称：羚锐制药 公告编号：2026-002 河南羚锐制药股份有限公司 董事减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、减持主体减持前基本情况 上述股份来源包括股权激励股份因资本公积转增股本所得。 上述减持主体无一致行动人。 1 披露的减持时间区间届满 重要内容提示： 董事持股的基本情况 河南羚锐制药股份有限公司(以下简称"公司")于 2025 年 9 月 16 日披露了 《 董 事 减 持 股 份 计 划 公 告 》， 具 体 内 容 详 见 上 海 证 券 交 易 所 网 站 （http://www.sse.com.cn/）公司公告。截至本公告披露之日，公司董事陈燕女 士持有公司股票 965,000 股，持股比例为 0.17%。 减持计划的实施结果情况 截至本公告披露之日，陈燕女士本次减持计划实施时间届满，其尚未减持公 司股票。 | 股东名称 | 陈燕 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 ...

近日，公司接到羚锐集团股份质押的通知，羚锐集团将其持有的公司无限售 流通股 1,700,000 股质押给中国农业银行股份有限公司新县支行，具体如下： 证券代码：600285 证券简称：羚锐制药 公告编号：2026-003 号 河南羚锐制药股份有限公司 关于大股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 河南羚锐集团有限公司（以下简称"羚锐集团"）持有河南羚锐制药股 份有限公司（以下简称"公司"）股票 121,817,898 股，占公司总股本的 21.48%。 本次质押 1,700,000 股后，羚锐集团累计质押本公司股份 30,050,000 股，占其 持股数量比例为 24.67%，占公司总股本的 5.30%。 截至本公告披露日，羚锐集团及其一致行动人持有本公司股份累计质押 数量为 30,050,000 股，占公司总股本的 5.30%。 一、本次股份质押基本情况 1.本次股份质押基本情况 | | | | | | | | | | 已质押股 | 未质押股 | | | --- | --- | ...